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Abstract
Objective. To report baseline articular, functional and ocular findings of the first international prospective
cohort study of Blau syndrome (BS).
Methods. Three-year, multicentre, observational study on articular, functional (HAQ, Childhood HAQ and
VAS global and pain), ophthalmological, therapeutic and radiological data in BS patients.
Results. Baseline data on the first 31 recruited patients (12 females and 19 males) from 18 centres in 11
countries are presented. Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and
11 various other NOD2 missense mutations; 20 patients were sporadic and 11 from five BS pedigrees.
Median disease duration was 12.8 years (1.157). Arthritis, documented in all but one patient, was oli-
goarticular in 7, polyarticular in 23. The median active joint count was 21. Functional capacity was normal
in 41%, mildly impaired in 31% and moderatesevere in 28% of patients. The most frequently involved
joints at presentation were wrists, ankles, knees and PIPs. On radiographs, a symmetrical non-erosive
arthropathy was shown. Previously unknown dysplastic bony changes were found in two-thirds of pa-
tients. Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and
moderatesevere visual loss in 33%. Expanded manifestations (visceral, vascular) beyond the classic
clinical triad were seen in 52%.
Conclusion. BS is associated with severe ocular and articular morbidity. Visceral involvement is common
and may be life-threatening. Bone dysplastic changes may show diagnostic value and suggest a
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previously unknown role of NOD2 in bone morphogenesis. BS is resistant to current drugs, suggesting the
need for novel targeted therapies.
Key words: Blau syndrome, sarcoidosis, NOD2, uveitis.
Rheumatology key messages
. Blau syndrome patients may show articular activity beyond 10 years and visceral/vascular involvement in 50%.
. Blau syndrome patients showed moderate/severe visual impairment in 1/3 and functional impact in 1/2.
. Radiological features of Blau arthritis include post-inflammatory and previously undescribed morphological bony
changes.
Introduction
Blau syndrome (BS) and early-onset sarcoidosis are re-
spectively the familial and sporadic forms of a dominantly
inherited granulomatous autoinflammatory disease that
results from mutations in or near the nucleotide oligomer-
ization domain of the NOD2 pattern recognition receptor
[16]. Our knowledge of the phenotype of BS has evolved
since the early descriptive series, mainly thanks to diag-
nostic genetic testing [47]. Classically associated with
the clinical triad of arthritis, dermatitis and uveitis, sys-
temic features, vasculitis and the involvement of various
organs/systems have become widely recognized in pa-
tients with BS [820]. Furthermore, the clinical diversity
of BS has become evident from the recent description
of patients carrying disease-causing NOD2 mutations,
but lacking the classic clinical triad [21]. At present, BS
is considered to be one of the monogenic systemic
autoinflammatory diseases.
To date, all studies on BS have been either short case
series or multicentre registries [22, 23] based on retro-
spectively collected data. The natural history of BS and
its functional consequences remain largely unknown. As
our knowledge of the putative pathogenic pathways
underlying BS progresses, we also need to prospectively
collect data on prognosis, natural history and the evolu-
tion of articular, ocular and visceral symptoms. Given the
rarity of BS, this can only be achieved via a multicentre
collaborative effort.
We are reporting herein the baseline results of a pro-
spective international study collecting patient history, clin-
ical and functional assessments, and radiological and
standardized ophthalmological evaluations using widely
used evaluation tools on the baseline visit from the first
31 recruited BS patients. This article contains a combin-
ation of historical data and cross-sectional evaluations
including physical and functional assessments, ophthal-
mological evaluation, and radiological data. To date, this
is the first and largest comprehensive analysis of BS fea-
turing a prospective study design.
Patients and methods
Investigators who participated in the Pediatric
Granulomatous Arthritis International Registry and
members of paediatric rheumatology societies (PReS,
Eurofever, PRINTO and the paediatric section of ACR)
were invited to join in this 3-year observational study.
Ethics committee or institutional review board approval
was obtained at the coordinating centre (University of
Leuven) and all participating sites.
Patients with BS and proven NOD2 mutations [22, 24]
were included after informed consent had been obtained.
Standardized data collection forms included descriptions
of triad (arthritis, dermatitis and uveitis) and expanded
manifestations, as well as medication use. The investiga-
tors were asked to report on the efficacy of treatments at
the time using the following categories: complete re-
sponse, partial response or failure. Articular assessment
comprised the number of active and limited joints as-
sessed by a paediatric or adult rheumatologist using the
75-joint count score. The presence of deformities (micro-
gnathia, swan neck, boutonnie`re, camptodactyly, brachy-
dactyly, genu valgus or other) was also recorded. Patient-
reported functional status via the Childhood HAQ (CHAQ)
or HAQ, and 100 mm VAS for pain and global status of
well-being were collected. For the CHAQ, parent reporting
was used for patients aged 49 years. A single-view wrist
and hand X-ray was obtained. All plain films were scored
for specific radiological features by a musculoskeletal
radiologist (S.P.). Radiographic features were divided
into two categories: arthritis-related features and morpho-
logical changes. Arthritis-related radiological signs con-
sidered were soft tissue swelling, periarticular
osteopenia, joint space narrowing, bony ankylosis, epi-
physeal overgrowth and erosions. For children, the
Poznanski score was measured [25]. X-rays of healthy
age-matched children were used as controls. A compre-
hensive ophthalmological evaluation was obtained within
a month of each study visit by the patient’s treating oph-
thalmologist. Standardization of Uveitis Nomenclature
(SUN) classification was used to grade anterior uveitis.
Assessment of response to therapy was performed for
articular, ocular and expanded manifestations as part of a
post hoc analysis. At the time of the baseline visit, patients
with 53 months of drug exposure were classified as re-
sponders or non-responders according to the findings at
the baseline visit. For articular disease, if one or more
swollen joints was present, the patient was deemed to
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be a non-responder. For eye disease, if cells in the anter-
ior chamber, active vitritis or active retinal inflammation
were present, the patient was deemed to be a non-re-
sponder. As for the patient’s expanded manifestation,
analysis was based on the investigator’s input according
to a request for a narrative of the evolution of the
manifestation.
Descriptive statistics were used to report the data, and
the MannWhitney U-test was used to compare datasets.
VAS scores were converted to a 03 score by multiplying
each VAS value by a factor of 0.03. Next, the CHAQ, HAQ
and VAS well-being and pain scores were divided into four
categories of severity [26]: none (0), mild (>0 to 40.5),
moderate (>0.5 to 41.5) and severe (>1.5). To facilitate
comparisons, visual acuity was converted into logMAR
units by calculating the log of the visual acuity in the
decimal Snellen scale in metres. Normal visual acuity is
defined by a logMAR of 0.00.5, moderate visual impair-
ment from 0.6 to 1.0 and severe visual loss from >1.0.
Median and absolute range were used for description
(see Results section).
Results
Demographic and genetic data
This study included 31 patients (12 females and 19 males)
from 18 centres in 11 countries. Of the 31 patients, 23
were recruited from the Pediatric Granulomatous
Arthritis International Registry and 8 through rheumatol-
ogy societies. It was found that 11 patients were carrying
heterozygous p.R334W NOD2 mutations, 9 heterozygous
p.R334Q mutations, and the remaining 11 patients a var-
iety of different NOD2 mutations (E600K, Y563S, M514T,
A755V, G481D, T605P, G464W and C495Y). Twenty indi-
viduals had a sporadic form of the disease, while the re-
maining 11 patients belonged to five distinct BS
pedigrees. The study included 18 children and 13 adults,
with a median age at baseline evaluation of 16.5 years
(range 1.958). Median disease duration was 12.8 years
(range 1.157). Median age at onset of joint disease was 2
years (range 3 months to 13 years) and eye disease was
4.4 years (range 6 months to 22 years) (P< 0.001,
MannWhitney U-test). The median age at onset of skin
rash was 1.1 years (range 2 months to 20 years).
Cutaneous manifestations
Based on case histories at the baseline visits for this
study, the classical BS rash was described in a total of
25 patients. The appearance of this rash varied from pre-
dominantly papuloerythematous (five patients), mild scaly
eczematoid (eight patients), tan-coloured mildly scaly
(eight patients) to ichthyosiform (four patients). The
second most common cutaneous manifestation was ery-
thema nodosum (four patients). One patient had a leuco-
cytoclastic vasculitis.
Articular findings
Articular involvement was documented in all but one
patient. Arthritis onset was oligoarticular in 7 and
polyarticular in 23 patients. In the latter group, the
median joint count at onset was 15 (range 557). The
most commonly affected joints at presentation were
wrists (87%), knees (73%), ankles (63%) and PIP (53%).
One-third of patients had involvement of MCPs and/or
elbows. Rarely involved joints at onset were hips (9%),
spine (6%) and TM joints (3%). At baseline evaluation,
articular disease was active in 21 patients (70%) after a
median evolution of 12.8 years. The median active joint
count at the baseline visit [2, interquartile range (IQR) 7]
was significantly lower than the joint count at presentation
(15, IQR 14) (P< 0.001, MannWhitney U-test), suggesting
improvement of arthritis activity. At their baseline evalu-
ation, 81% of patients had limited joints, with a median
limited joint count of 6 (IQR 14), and 53% of patients had
deformities, with a median number of deformed joints of 8
(IQR 8). The most common deformities were noted at the
PIP joints, with camptodactyly observed in 19 patients. Of
the 19 patients with> 10 years of active disease at base-
line, 13 patients still had active arthritis with a median joint
count of 5 (IQR 10).
Functional outcomes
Functional capacity, as assessed by CHAQ and HAQ,
showed normal function in 41% of patients, mild impair-
ment in 31%, moderate in 17% and severe in 11%.
Median VAS scores for well-being and pain were 15
(IQR 39) and 13 (IQR 48), respectively. Almost half of BS
patients (48%) reported a moderate to severe impact of
the disease on their global well-being, while 26% of pa-
tients reported no impact. Similarly, moderate to severe
pain was reported by 43% of patients and 32% experi-
enced no pain. Fig. 1 shows the distribution of BS patients
according to categories of function, well-being and pain.
Radiographic findings
Plain radiographs of hands and wrists of 13 children (aged
between 5.9 and 16 years) and 11 adults were reviewed.
Typical arthritis-related features were symmetrical in both
children and adults and are summarized in Table 1.
Dysplastic changes are shown in Figs 2 and 3. They
include camptodactyly (flexion contracture in PIP joints),
carpal dysplasia with carpal crowding (changes in shape
and position affecting bones in the proximal carpal row)
not due to narrowing, an abnormal distal radial epiphysis
with a biconcave articular surface (prominent bony ridge
in contact with the scapholunate joint), an abnormal shape
of the distal ulna (plump ulna), a short ulna and abnormal
shape of the second metacarpal bone (long small diaph-
ysis). In children, radiographic camptodactyly, carpal dys-
plasia, biconcave radius, plump ulna and abnormal shape
of the second metacarpal were seen in 59%, 68%, 64%,
32% and 32%, respectively. In adults, the same bone
deformities were seen at higher frequencies, specifically
63%, 88%, 100%, 81% and 63%. The average Poznanski
index in all paediatric patients increased from 9% to 24%
compared with an age-matched control group (P< 0.05).
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Ophthalmological findings
A total of 25 patients (81%) had ocular involvement, with
96% (24/25) exhibiting bilateral disease. Anterior uveitis
was seen in all patients and was associated with posterior
involvement in 72%. Intermediate uveitis was observed in
52% of patients. After a median disease duration of 12.1
years (range 0.7553), 36% of patients had anterior uveitis
activity, 64% had active vitreous inflammation, 18%
showed active chorioretinitis and 5% had active retinal
vasculopathy. Complication rates for anterior involvement
were synechiae in 64%, cataracts in 55%, band
keratopathy in 23% and increased intraocular pressure
in 36%. Posterior disease sequelae included optic atrophy
and macular oedema in 14% and retinal detachment in
9% of cases. Visual acuity data in 22 of 25 patients
showed a mean decimal Snellen for corrected visual
acuity of 7.2 (range 0.110) for the right eye and 6.5
(range 0.510) for the left. Using the logMAR scale, 68%
of patients had normal acuity, with 18% and 14% showing
moderate and severe visual loss, respectively.
Expanded manifestations
Clinical manifestations beyond the classical triad included
systemic, vascular and visceral organ involvement and
were observed in 16 of the 31 patients (52%). Of these
16 patients, 14 exhibited the three triad components, 1
had only cutaneous components and 1 only joint disease.
Table 2 shows the clinical characteristics of the expanded
manifestations.
Medication use at baseline visit
Systemic medication was being administered to 30 pa-
tients, with 70% receiving a combination of immunosup-
pressive drugs and/or biologic therapy with systemic
corticosteroids. Table 3 lists the anti-inflammatory and
FIG. 2 BS-related radiological findings in a representative
adult patient (38 years)
Diffuse peri-articular osteopenia and joint space narrow-
ing in the PIP and wrist joints (short arrows). Dysplasia of
the scaphoid and lunate bone (arrowhead). Associated
biconcave radial epiphysis and abnormal plump distal
ulna (longarrows) were typical of the Blau hand.
FIG. 1 Percentages of patients (y-axis) in the vari-
ous groups of functional severity utilizing converted
units of CHAQ/HAQ and VASs as described in
Patients and methods
The CHAQ/HAQ data are for 29 patients, the VAS on
well-being for 27 patients and the VAS on pain for 28
patients. Individual patients fall into separate severity
groups for different variables.
TABLE 1 Arthritis-related findings in X-rays of hands and
wrists in Blau syndrome, expressed as percentages (total
of 45 hands)
Soft
tissue
swelling Osteopenia
Joint
space
narrowing Erosions
DIP 0 36 9 0
PIP 2 78 56 0
MCP 0 80 9 0
Phalanges 2 0 0 0
Metacarpal 0 0 0 0
CMC 0 62 22 0
Carpal 0 64 47 0
Radiocarpal 0 40 38 0
DRUJ 0 13 29 0
Radius 0 0 0 0
Ulna 0 0 0 0
DRUJ: distal radioulnar joint.
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FIG. 3 BS-related radiological features in four children
Plain films of hands and wrists showing typical morphological changes including: (i) rotation and pseudo-collapse of the
lunate and scaphoid bone (arrowheads in upper right and lower left panels); (ii) different grades of dysplasia of ulnar and
radial epimetaphysis (biconcave shape) (long arrows in upper right and lower left panels); (iii) ulnar shortening, from subtle
to severe grade (long arrows in upper right, lower left and lower right panels); and (iv) long and small diaphysis of the MC2
(sharp arrow in upper and lower left panels). Note the presence of osteopenia in hands and wrists. In one child, the PIP-
contracture is present in four fingers (long arrows in lower left panel). In other children, camptodactyly and carpal
dysplasia are more subtle.
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immunosuppressive drugs for all patients, as well as the
judgement of their actual efficacy on articular, ocular and
expanded manifestations. All patients had at least 3
months of exposure to the current treatment at baseline.
Discussion
We herein describe data from baseline visits for a pro-
spective cohort study set up to better understand the nat-
ural history of BS. This multicentre study involved direct
examination of 31 patients with documented NOD2 muta-
tions by rheumatologists and ophthalmologists utilizing a
standardized clinical report form, and constitutes the lar-
gest prospectively assembled study to date on BS.
Inflammatory eye disease in BS is frequent and most
often involves both the uveal tract and the posterior seg-
ment. In the present study, uveitis was seen more fre-
quently than in a previous retrospective BS registry [17].
In a Canadian cohort of 1081 JIA patients focusing on
ocular involvement, Saurenman et al. [27] found uveitis
in only 13.1% of all JIA patients and in 12.5% of patients
with polyarticular JIA (n= 256). In our study, more than
one-third of BS patients manifested active anterior uveitis,
with a median disease duration of 12.1 years. Posterior
involvement was seen in 72% of patients, but was not
seen in any of the 142 JIA patients in the Canadian
series, while vitreous involvement was seen in only
3.5%. Although the different lengths of follow-up have to
be taken into account, the frequency of anterior uveitis
complications in our study exceed those of the
Canadian study with frequencies for synechiae, cataracts,
glaucoma and band keratopathy being twice as high.
Macular oedema was found in 14% of BS patients com-
pared with 4.9% of the Canadian patients [27]. Moderate
or severe visual loss was seen in 32% of our patients
compared with 13% of the JIA cohort. In one study,
worse visual impairment was linked to the p.R334W
NOD2 mutation [28], whereas in our study, we found no
specific NOD2 mutations associated with more severe
visual impairment (logMAR> 0.5).
The characteristics of arthritis in BS, comprising boggy
synovitis and tenosynovitis, are distinct from those
observed in both JIA and RA. We found a differential pat-
tern of joint involvement, with very rare involvement of
axial joints, hips and TM joints. We noted radiographic
features in BS patients that are different from those in
JIA and RA. Whereas periarticular osteopenia and joint
space narrowing typically involving the PIPs and carpal
joints were relatively frequent, the most distinguishing fea-
ture observed in our cohort was the virtual absence of
marginal erosions, notably including patients with long-
standing arthritis. Different from adult RA is the rarity of
severe MCP joint involvement as well. The presence of a
symmetrical non-erosive arthritis could help recognition of
BS when evaluating a patient with suspected RA. The vir-
tual absence of epiphyseal overgrowth (data not shown)
may help to differentiate the Blau hand from a polyarticu-
lar JIA hand.
This is the first report to document a number of radio-
logical dysplastic changes that contribute to a typical Blau
hand. Of interest is the high frequency and early onset of
camptodactyly, a contracture virtually limited to the PIP
joints, which has been previously described as a clinical
characteristic in early reports [4, 7] and documented as a
radiological feature in 48% of young and 64% of adult
patients in our study. This deformity is the most consistent
contracture found in all BS patients. It should be noted
that camptodactyly is reported in association with more
than 180 recognized genetic syndromes [from Online
Mendelian Inheritance in Man (OMIM)]. Further, previously
TABLE 2 Clinical description and NOD2 mutations observed in 16 patients with expanded manifestations
Patient NOD2 mutation Expanded manifestations
4 R334Q GL
5 R334Q Transient facial palsy
6 R334Q ILD, pulmonary embolism (single episode)
7 R334Q Hepatomegaly (hepatic granuloma), GL (granulomatous), ILD, sialadenitis, EN
9 R334Q HT
10 R334W HT, GL
13 R334W Recurrent fever, GL
14 R334W Recurrent fever, GL, interstitial nephritis (granulomatous)
16 A755V Recurrent fever, EN, HT, ILD, interstitial nephritis
17 G481D GL, splenomegaly (required splenectomy), ILD, transient facial palsy, HT, ischaemic
stroke, nephrocalcinosis
19 R334W EN
21 E383K GL, hepatomegaly, splenomegaly
24 G464W HT, large vessel vasculitis (Takayasu’s-like), hepatomegaly
25 C495Y Hepatitis (granulomatous), splenomegaly
27 R334W ILD, nephrocalcinosis
28 R334Q Recurrent fever, EN, leucocytoclastic vasculitis, interstitial and glomerulonephritis
(granulomatous)
HT: hypertension; EN: erythema nodosum; GL: generalized lymphadenopathy; ILD: interstitial lung disease.
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unrecognized dysplastic findings include an abnormal
morphology of the bones of the first carpal row (seen in
91% of the adult patients), a biconcave radial distal
epiphysis, a plump distal ulna, and a long thin diaphysis
of the second metacarpal bone. The underlying mechan-
ism for these changes is unclear, yet in view of their pres-
ence in both young and adult patients, we suspect they
are not a consequence of post-inflammatory bone re-
modelling. Dysplastic bone changes are described in
chronic infantile neurological cutaneous articular/neonatal
onset multisystem inflammatory disease (CINCA/NOMID)
syndrome, a dominantly inherited autoinflammatory dis-
order associated with gain of function mutations in the
NLRP3 gene, encoding cryopyrin, a protein that shares
both structural and functional characteristics with NOD2
[29]. In CINCA/NOMID syndrome, enlargement of the non-
ossified portion of the physis is followed by splaying and
cupping of the metaphysis, with later calcification of a
paraphyseal mass. A role for cryopyrin in chondrocyte
apoptosis has been suggested [30]. Although the dysplas-
tic changes observed in BS are less severe and rather
epiphyseal than metaphyseal, they could well be the
result of abnormal pathways in bone or cartilage morpho-
genesis in which NOD2 may have a role.
This study is also the first to look at functional capacity
in a cohort of patients with BS. The functional status of
these patients was not dissimilar to that found in a cross-
sectional study of 21 polyarticular JIA patients cared for at
a tertiary centre [31]. In fact, the value for moderate or
severe CHAQ/HAQ was 33% in JIA, while for BS it was
37.8%. Overall, well-being was moderately or severely
impaired in 30% of the JIA group and more frequently
impaired in 49% of our BS cohort, while moderate to
severe pain perception was 35% for JIA and 43% for
the BS cohort [31].
Although arthritis, uveitis and dermatitis are the diag-
nostic bedrock for the clinician at disease onset, with
increasing awareness of and availability of genetic testing,
several non-triad manifestations of BS have been docu-
mented in recent years [823]. We reported an expanded
phenotype in one-third of patients in a retrospective study
[17]. Here, probably as a result of more intensive and
standardized data collection, we found expanded mani-
festations in 48% of BS patients. Physicians caring for BS
patients should be aware of the possibility of visceral in-
volvement, as well as the possibility of large vessel vas-
culitis with potential life-threatening course. The present
cohort included one child whose main manifestation was
a Takayasu’s-like arteritis [21]. Fatal pulmonary hyperten-
sion has been observed in one case (not in this cohort) by
one of the authors (C.D.R.), and severe systemic hyper-
tension was found in >20% of the present cohort. The
underlying mechanism is probably multicausal. Of the
five patients with hypertension, two have some form of
renal disease (one interstitial nephritis and one nephrocal-
cinosis) and one developed large vessel vasculitis
(Takayasu’s-like) with involvement of the renal artery. In
one patient, whose hypertension began at the age of 5
years, there was no large vessel involvement by digital
angiography and no renal disease. We hypothesized a
form of intermediate-sized vasculopathy of the kidney;
his response to angiotensin-converting enzyme inhibitors
was dramatic. The other patient developed hypertension
at the age of 40 years and continues to be exposed to
chronic use of corticosteroids to control severe eye dis-
ease. Also fever, lymphadenopathy and hepatospleno-
megaly were relatively frequent and mostly clustered in
the same patients. BS presents as a systemic inflamma-
tory illness suggestive of systemic JIA, as has been re-
ported earlier by Arostegui et al. [23].
More than two-thirds of BS patients received medical
therapy, often combining systemic steroids, immunosup-
pressive and/or biologic drugs. Despite this, up to 70% of
patients had evidence of active arthritis, 61% had vitreous
inflammation and 35% had active anterior uveitis at evalu-
ation. TNF-a inhibition was the most commonly used
TABLE 3 Medication use: anti-inflammatory and im-
munosuppressive drugs and responses at baseline for
different disease manifestations
Patient
Systemic
drugs
Topical
steroids
Articular
control
Ocular
control
Expanded
disease
resolved
1 — Yes Yes No NA
2 MTX, CS No No NA NA
3 MTX No No NA NA
4 MTX, CS Yes No No No
5 A, MTX, CS Yes No No Yes
6 CS No No Yes Yes
7 CS, I No No No Yes
8 I Yes No No NA
9 CS, A Yes No No Yes
10 CS, A Yes No No Yes
11 MTX NA No NA NA
12 CS, MTX, C Yes Yes No NA
13 A, MTX Yes No No Yes
14 MTX, CS, A Yes No No Yes
15 MTX, A Yes Yes No NA
16 MTX, A NA NA NA Yes
17 Th, CS Yes No No No
18 MTX, A Yes Yes No NA
19 CS, A Yes No No No
20 MTX, A Yes No No NA
21 I Yes Yes Yes Yes
22 MTX, I No Yes No NA
23 CS Yes No No NA
24 CS, MTX NA Yes NA No
25 CS No No Noa Nob
26 MTX, A No Yes Yes NA
27 CS, MTX, A Yes No No Yes
28 CS, MMF No No No Noc
29 CS, A No No No NA
30 CS NA No NA NA
31 MTX No No No NA
CS: systemic corticosteroids; I: Infliximab; A: adalimumab;
C: canakinumab; TH: thalidomide; NA: manifestation not
present. aHad end-stage eye disease. bHepatomegaly
resolved, splenomegaly persisted. cFever persisted.
www.rheumatology.oxfordjournals.org 7
Blau syndrome
therapy, which seemingly helps in achieving partial control
of articular disease. The role of IL-1 and IL-1 blockade in
BS is unclear. Arostegui et al. [23] found clinical
improvement and downregulation of plasma cytokines in
one patient treated with anakinra, and more recently
Simonini et al. [32] reported effectiveness for posterior
uveitis with canakinumab. Martin et al. [33] also found
no response to anakinra in one BS patient with ocular
disease.
To our knowledge, this is the largest collection of BS
patients reported to date and providing a combination of
retrospective and prospectively collected clinical, oph-
thalmological and radiological data. Since the disease
course of BS is prolonged, the baseline data offer com-
prehensive information on the natural course of the dis-
ease to the point of inception. An additional advantage of
this prospective cohort is that it will offer the possibility of
assessing the impact of ongoing treatments on dis-
ease progression. We acknowledge that reliance on
retrospective collection of physical findings at onset
based on record review is a weakness of this study;
hence, comparisons between baseline and onset sta-
tus should be interpreted with caution. As the study con-
tinues during the next few years, the robustness of the
data on the natural history of the disease is expected to
increase.
In conclusion, our study confirms that BS is associated
with severe ocular and articular morbidity. Systemic ill-
ness and visceral involvement are common and may be
life-threatening. A novel finding described in this study
was the presence of bone dysplastic changes in affected
hands, the mechanism for which needs further study. BS
seems to be resistant to currently available therapies in
many patients, suggesting that early intervention and the
development of novel therapies will be paramount in alter-
ing the course of the disease.
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